This appears in Fierce Pharma online.
By Kelly Waller
While it’s true that artificial intelligence can occasionally falter, the last thing we want to do is compound these errors with misinformed data strategies. The risks are significant, particularly in the context of AI engagement.
This can be a tall order as the global pharmaceutical industry races to adopt AI technologies for patient engagement. Generative AI alone could unlock $110 billion in economic value annually for pharmaceutical and medical product companies, according to a 2024 McKinsey & Co. report.
Indeed, AI tech can produce blockbuster results. Novo Nordisk, the maker of the Ozempic, uses AI to process large volumes of data for clinical trials. These insights could improve drug adherence by pinpointing patient motivations and compliance challenges.
However, the urgency to incorporate AI into an overall data strategy can cause pharmaceutical companies to miss potential hazards, resulting in patients receiving the wrong messages. In our experience, five strategic factors can make a company vulnerable to these mistakes.
